Seattle Buys Into Future of Genmab ADC Deal
Executive Summary
In a six-year-old collaboration with Genmab, Seattle Genetics has decided to exercise its option to co-develop and co-commercialize tisotumab vedotin, an antibody-drug conjugate for solid tumors, granting both companies a 50:50 share.
You may also be interested in...
Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.
ECHELON-2 Ushers In Another New Adcetris Indication For Seattle Genetics
The combination of Adcetris with chemotherapy improved progression-free and overall survival in peripheral T-cell lymphoma. Filing is expected soon, and approval will help the product reach blockbuster status.
Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal
Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.